Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens
Proceedings of the National Academy of Sciences · 18.04.2023 · 120 (16)
DOI: 10.1073/pnas.2220134120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.04.2023. Verfasst von Shaela Wright und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38105. Hauptthemen laut MEDLINE: Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, V Foundation for Cancer Research, American Cancer Society.
Abstract (Originalsprache)
Bromo- and extra-terminal domain inhibitors (BETi) have exhibited therapeutic activities in many cancers. However, the mechanisms controlling BETi response and resistance are not well understood. We conducted genome-wide loss-of-function CRISPR screens using BETi-treated KMT2A-rearranged (KMT2A-r) cell lines. We revealed that Speckle-type POZ protein (SPOP) gene (Speckle Type BTB/POZ Protein) deficiency caused significant BETi resistance, which was further validated in cell lines and xenograft models. Proteomics analysis and a kinase-vulnerability CRISPR screen indicated that cells treated with BETi are sensitive to GSK3 perturbation. Pharmaceutical inhibition of GSK3 reversed the BETi-resistance phenotype. Based on this observation, a combination therapy regimen inhibiting both BET and GSK3 was developed to impede KMT2A-r leukemia progression in patient-derived xenografts in vivo. Our results revealed molecular mechanisms underlying BETi resistance and a promising combination treatment regimen of ABBV-744 and CHIR-98014 by utilizing unique ex vivo and in vivo KMT2A-r PDX models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38105.
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105.
- Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
- Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105.
- Division of Hematology/Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294.
ORCID-Profile: Shaela Wright, Jianzhong Hu, Yang Zhang, Chunliang Li
Förderung
- NCI NIH HHS
- V Foundation for Cancer Research
- American Cancer Society
- HHS | NIH | National Cancer Institute
Zitieren
APA
Wright, S., Hu, J., Wang, H., Hyle, J., Zhang, Y., Du, G., Konopleva, M. Y., Kornblau, S. M., Djekidel, M. N., Rosikiewicz, W., Xu, B., Lu, R., Yang, J. J., & Li, C. (2023). Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proceedings of the National Academy of Sciences, 120(16). https://doi.org/10.1073/pnas.2220134120
Vancouver
Wright S, Hu J, Wang H, Hyle J, Zhang Y, Du G, et al. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proceedings of the National Academy of Sciences. 2023;120(16). doi:10.1073/pnas.2220134120
BibTeX
@article{Wright2023,
author = {Wright, Shaela and Hu, Jianzhong and Wang, Hong and Hyle, Judith and Zhang, Yang and Du, Guoqing and Konopleva, Marina Y and Kornblau, Steven M and Djekidel, Mohamed Nadhir and Rosikiewicz, Wojciech and Xu, Beisi and Lu, Rui and Yang, Jun J and Li, Chunliang},
title = {Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {16},
doi = {10.1073/pnas.2220134120}
}
EUVIMED